The Year of the Rat has witnessed continual seismic and historical turns and twists. As the Oxford Dictionary describes, 2020 “cannot be neatly accommodated in one single word”. With this chaotic backdrop, China’s legal market has, however, proven its resilience.

Professional services have been valued more than ever in a year crippled by the pandemic and global trade disputes. In-house counsel and business executives spared no words in expressing their gratitude and appreciation to nominated lawyers for their excellence and service consciousness during these hard times, actions that often may have secured their clients’ survival.
After battling the global health crisis, the world is betting big on a covid-19 vaccine to pull humanity from the pandemic. As multinational pharmaceutical companies have raced to develop a vaccine, and eye the nearly limitless monetary potential fuelled by global demand, an important question emerges of how to strike a balance between protecting public health and IP rights? IP profit v human loss explores the feasibility of compulsory licensing, which governments may impose, and discusses what pharma companies should be concerned about in their vaccine pricing strategies.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.



















